EFFECT OF MYO INOSITOL VERSUS METFORMIN ON QUALITY OF LIFE IN POLYCYSTIC OVARIAN SYNDROME IN WOMEN
Jyoti Kaushal, *Jyoti Nehra, Savita Rani Singhal and Veena Singh Ghalaut
Introduction: In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain and body hair, menstrual disturbances and infertility result in psychological distress and reduced quality-of-life. Metformin and Myo-inositol being insulin sensitizers improve biochemical, clinical and reproductive parameters in PCOS in women.This study was done to compare the quality of life of Myo-inositol versus Metformin in PCOS in women. Material & Methods: A prospective, open labeled, randomized, comparative, clinical study was conducted on 60 patients. The patients were randomly divided in two groups of 30 each to receive either of the following two treatments: Group A: Tab Myo-inositol 1g twice daily. Group B: Tab Metformin 500mg thrice daily for 24 weeks. QOL assessment was done by HRQOL questionnaire by Cronin et al. at week 0, 12 and 24. Five domains i.e. emotions, body hair, weight, infertility and menstrual problems were assessed. Results: There was significant improvement in QOL parameters, in all the five domains in both the groups over a period of 24 weeks. However, on comparing both the groups at 24 weeks, there was no significant difference in all the five domains. Conclusion: Metformin and Myo-inositol are used for the treatment of PCOS. These drugs improve insulin resistance, menstrual irregularities, hyperandrogenism and infertility. QOL which is reduced in PCOS, was assessed by the administration of both of these drugs. Although there was a definite improvement in QOL with both types of treatment in PCOS in women but on comparing both the groups no significant difference was observed.
Keywords: HRQOL, Metformin, PCOS, Myo-inositol, Insulin sensitizers.
[Full Text Article]